Effects of n-3 PUFA supplementation on oocyte in vitro maturation in mice with polycystic ovary syndrome

Ma, Rujun; Wang, Shuxian; Xue, Mengqi; Zhang, Hong; He, Zhaowanyue; Jueraitetibaike, Kadiliya; Ge, Xie; Chen, Li; Yao, Bing

doi:10.1186/s13048-023-01162-w

Cited by 11 publications

(7 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three-week-old C57BL/6 mice were randomly divided into 2 groups ( n = 18 for each group) and were injected with dehydroisoandrosterone (DHEA, Macklin, Shanghai, China)(6 mg/100 g body weight) and sesame oil (Macklin, Shanghai, China) for 21 consecutive days respectively as described previously [ 66 ]. All mice were anesthetized with 3% isoflurane (ISO) (in 40% oxygen) and were euthanized by bloodletting prior to dissection at preset time intervals.…”

Section: Methodsmentioning

confidence: 99%

ApoC3 is expressed in oocytes and increased expression is associated with PCOS progression

Zhou,

Mo,

Feng

et al. 2023

J Ovarian Res

View full text Add to dashboard Cite

Background Polycystic ovary syndrome (PCOS) is a lifelong metabolic disorder and the most common cause of anovulatory infertility affecting women in reproductive age. Our recent study reported that apolipoprotein C3 (ApoC3) could be a potential diagnostic serum marker for metabolism disturbance in PCOS patients, but whether it is present in the ovaries and what role it plays has not yet been described. Objective Aimed to investigate ApoC3 expression in ovary of PCOS, and to discuss its potential role in PCOS progression. Methods ApoC3 expression in ovarian tissue samples from 12 PCOS patients along with 12 healthy controls were measured via immunohistochemistry (IHC). Also, the level of ApoC3 in follicular fluid from 14 patients diagnosed with PCOS and 13 control subjects were detected by ELISA. The expression and location of ApoC3 in ovaries of PCOS mice were tested weekly for three consecutive weeks during PCOS formation using real time PCR, Western Blot, IHC and immunofluorescence. The relation of ApoC3 and sex hormones was analyzed in mouse plasma. Additionally, the dynamic changes of ApoC3 level in ovaries of healthy mice during postnatal development was also investigated. Results ApoC3 levels in ovarian tissue and follicular fluid were significantly higher in PCOS patients than in controls (33.87 ± 4.11 vs. 27.71 ± 3.65, P < 0.01; 0.87 ± 0.09 vs. 0.51 ± 0.32 ng/mL, P < 0.05), respectively. In ovary, ApoC3 was found to be located in the cytoplasm of oocyte, and its expression gradually increased with PCOS progression (P < 0.05). Furthermore, correlation analysis showed that plasma ApoC3 level was closely associated with luteinizing hormone (r = 0.709, P = 0.001), testosterone (r = 0.627, P = 0.005) and anti-mullerian hormone (r = 0.680, P = 0.002) in PCOS mice. In addition, ApoC3 level in oocyte was physiologically increased and peaked on postnatal age 21 (P21), then decreased following P21 in healthy mice. Conclusions We identified ApoC3 expression in oocyte. It may be involved in PCOS progression and possibly participate in the regulation of oocyte development.

show abstract

Section: Methodsmentioning

confidence: 99%

ApoC3 is expressed in oocytes and increased expression is associated with PCOS progression

Zhou,

Mo,

Feng

et al. 2023

J Ovarian Res

View full text Add to dashboard Cite

show abstract

“…It is important to highlight that different types of PUFAs affect oocyte quality differently. ω3-PUFAs can decrease abnormal oxidative stress levels and spindle/chromosome aberration rates in oocytes [103]. The consumption of long-chain ω3-PUFAs safeguards reproductive function and is linked to a greater likelihood of successful reproduction in women undergoing assisted reproduction [104,105].…”

Section: Lipid Metabolismmentioning

confidence: 99%

Ovarian aging: energy metabolism of oocytes

Bao,

Yin,

Liu

2024

J Ovarian Res

View full text Add to dashboard Cite

In women who are getting older, the quantity and quality of their follicles or oocytes and decline. This is characterized by decreased ovarian reserve function (DOR), fewer remaining oocytes, and lower quality oocytes. As more women choose to delay childbirth, the decline in fertility associated with age has become a significant concern for modern women. The decline in oocyte quality is a key indicator of ovarian aging. Many studies suggest that age-related changes in oocyte energy metabolism may impact oocyte quality. Changes in oocyte energy metabolism affect adenosine 5'-triphosphate (ATP) production, but how related products and proteins influence oocyte quality remains largely unknown. This review focuses on oocyte metabolism in age-related ovarian aging and its potential impact on oocyte quality, as well as therapeutic strategies that may partially influence oocyte metabolism. This research aims to enhance our understanding of age-related changes in oocyte energy metabolism, and the identification of biomarkers and treatment methods.

show abstract

“…Alam et al proposed that SIRT1 may prevent cell dysfunction by reducing oxidative stress-induced cell damage [21]. In recent years, there have been increasing studies on the role of SIRT1 in anti-oxidative stress [21][22][23], but few studies have investigated its antioxidant effect in premature ovarian failure (POF). It has been reported that the activation of AMPK can activate SIRT1 (histone deacetylase 1) [24], additionally, PPAR-γ (peroxisome proliferator-activated receptor γ) has been reported to act as a transcription factor that inhibits SIRT1 gene expression, and the expression of PPAR-γ is inhibited by AMPK [25,26].…”

Section: / 34mentioning

confidence: 99%

Metformin protects ovarian granulosa cells in chemotherapy-induced premature ovarian failure mice through AMPK/PPAR-γ/SIRT1 pathway

Yang,

Tang,

Yao

et al. 2023

Preprint

View full text Add to dashboard Cite

The incidence of premature ovarian failure (POF) is progressively escalating, with chemotherapy drugs identified as a significant contributing factor. Our study demonstrates that chemotherapy drugs can induce abnormal inflammation and oxidative stress within the ovary, resulting in damage to granulosa cells (GCs), which may be a significant cause of POF. Furthermore, numerous studies have reported Metformin (MET) has various beneficial effects, including anti-aging, anti-oxidative stress, and anti-inflammatory. Hence, the objective of this study is to investigate whether MET can be utilized for the treatment of chemotherapy-induced ovarian inflammation and the improvement of premature aging. Our vivo experiments conducted on animal models indicate that oral administration of MET ameliorates chemotherapy-induced ovarian damage and alleviates hormonal disruption in mice with POF by reducing inflammatory and oxidative stress-related harm. In our in vitro experiments, we aimed to simulate the inflammatory condition present within the ovary by indirectly co-culturing primary GCs with M1 macrophages. We observed injury to GCs caused by M1 macrophage supernatants was mitigated by treatment with MET. To validate the potential pathways involved in the action of MET, we observed that MET ameliorated GCs damage induced by M1 macrophages, possibly through the activation of the AMPK/PPAR-γ/SIRT1 pathway.

show abstract

Effects of n-3 PUFA supplementation on oocyte in vitro maturation in mice with polycystic ovary syndrome

Cited by 11 publications

References 43 publications

ApoC3 is expressed in oocytes and increased expression is associated with PCOS progression

ApoC3 is expressed in oocytes and increased expression is associated with PCOS progression

Ovarian aging: energy metabolism of oocytes

Metformin protects ovarian granulosa cells in chemotherapy-induced premature ovarian failure mice through AMPK/PPAR-γ/SIRT1 pathway

Contact Info

Product

Resources

About